Barcelona-based HealthTech company Biorce has raised €43.8M ($52M) in a Series A funding round to expand internationally, advance product development, and scale its team as demand grows for faster, more efficient clinical trials.
The round includes new investment from DST Global Partners, alongside increased participation from existing backers Norrsken VC and YZR Capital, as well as Mustard Seed Maze. A group of high-profile angel investors also joined the round, including Arthur Mensch (Mistral AI), Albert Nieto (Seedtag), Paulo Rosado (OutSystems), and Nik Storonsky (Revolut).
Biorce says the financing represents the largest Series A ever raised in the Iberian HealthTech and AI sector. Combined with earlier Seed rounds totaling €8.5M in 2024 and 2025, the company has now raised more than €50.6M ($60M) since its founding.
Tackling delays and inefficiencies in clinical research
Founded in 2024, Biorce focuses on reducing the time and cost required to run clinical trials. Drug development typically takes close to 11 years and costs more than €5B per therapy, with more than half of trials requiring protocol amendments that delay recruitment and significantly increase budgets.
According to the company, protocol amendments alone often pause trials for weeks and add hundreds of thousands of euros in additional costs, contributing to billions in inefficiencies across the industry each year.
Advertisement
Aika brings explainable AI to trial design
Biorce’s core product, Aika, is an AI-powered platform designed to shorten trial preparation and reduce protocol amendments. Built on data from roughly one million clinical trials, Aika supports protocol development, feasibility analysis, and site selection, helping pharmaceutical companies, biotech firms, and CROs accelerate development timelines by up to 50%.
Unlike many black-box AI tools, Biorce emphasizes explainability. Each recommendation generated by Aika is fully documented and defensible for regulatory review, allowing teams to justify decisions to authorities such as the FDA and EMA while keeping experts in control through a human-in-the-loop approach.
The platform is already being used across multiple therapeutic areas, including oncology, neurology, and rare diseases.
Expansion into the U.S. and rapid team growth
The new capital will support Biorce’s international expansion, with a particular focus on entering the U.S. market. The company plans to open a development and R&D hub in Austin, Texas, as part of this next phase.
Biorce also aims to grow its workforce to around 250 employees by the end of 2026, primarily across engineering and commercial roles. The company reported finishing last year roughly 200% above its revenue target, signaling strong market traction.
In early 2026, Biorce plans to further enhance Aika’s protocol intelligence and introduce new modules covering contract management, negotiation, budgeting, and operational planning. To support continued growth, the company is also relocating to larger offices in Barcelona.
About Biorce
Biorce is a Barcelona-based HealthTech company using AI to transform how clinical trials are designed and executed. Its platform, Aika, reduces delays, cuts costs, and improves operational efficiency, helping life-saving therapies reach patients faster by rethinking the foundations of clinical research.
